Abstract:Introduction: Genetic mutations in critical nodes of pulmonary epithelial function are linked to the pathogenesis of pulmonary fibrosis (PF) and other interstitial lung diseases. The slow progression of these pathologies is often intermitted and accelerated by acute exacerbations, complex non-resolving cycles of inflammation and parenchymal damage, resulting in lung function decline and death. Excess monocyte mobilization during the initial phase of an acute exacerbation, and their long-term persistence in the lung, is linked to poor disease outcome. Methods: The present work leverages a clinical idiopathic PF dataset and a murine model of acute inflammatory exacerbations triggered by mutation in the alveolar type-2 cell-restricted Surfactant Protein-C [SP-C] gene to spatially and phenotypically define monocyte/macrophage changes in the fibrosing lung. Results: SP-C mutation triggered heterogeneous CD68 + macrophage activation, with highly active peri-injured cells relative to those sampled from fully remodeled and healthy regions. Ingenuity pathway analysis of sorted CD11b - SigF + CD11c + alveolar macrophages defined asynchronous activation of extracellular matrix re-organization, cellular mobilization, and Apolipoprotein E ( Apoe) signaling in the fibrosing lung. Cell-cell communication analysis of single cell sequencing datasets predicted pro-fibrogenic signaling ( fibronectin/Fn1, osteopontin/Spp1 , and Tgfb1 ) emanating from Trem2/TREM2 + interstitial macrophages. These cells also produced a distinct lipid signature from alveolar macrophages and monocytes, characterized by Apoe expression. Mono- and di-allelic genetic deletion of ApoE in SP-C mutant mice had limited impact on inflammation and mortality up to 42 day after injury. Discussion: Together, these results provide a detailed spatio-temporal picture of resident, interstitial, and monocyte-derived macrophages during SP-C induced inflammatory exacerbations and end-stage clinical PF, and propose ApoE as a biomarker to identify activated macrophages involved in tissue remodeling.

MAV(S)erick mitochondria: an unconventional role for mitochondrial antiviral signalling protein in pulmonary fibrosis

Mitochondrial antiviral signaling protein is crucial for the development of pulmonary fibrosis

Post-translational regulation of PGC-1α modulates fibrotic repair.

Increased Flux Through the Mevalonate Pathway Mediates Fibrotic Repair Without Injury.

Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosis

Role of MicroRNAs in Signaling Pathways Associated with the Pathogenesis of Idiopathic Pulmonary Fibrosis: A Focus on Epithelial-Mesenchymal Transition

Mitochondrial Dysfunction as a Pathogenic Mediator of Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis

Prospects for Treatment of Idiopathic Pulmonary Fibrosis

Revisiting the role of MicroRNAs in the pathogenesis of idiopathic pulmonary fibrosis

Dysregulated Cell–Cell Communication Characterizes Pulmonary Fibrosis

Impaired AMPK Control of Alveolar Epithelial Cell Metabolism Promotes Pulmonary Fibrosis

Monocytes and macrophages: emerging mechanisms and novel therapeutic targets in pulmonary fibrosis

The Role of Interaction between Mitochondria and the Extracellular Matrix in the Development of Idiopathic Pulmonary Fibrosis

Spatial and phenotypic heterogeneity of resident and monocyte-derived macrophages during inflammatory exacerbations leading to pulmonary fibrosis

Evolving Perspectives on Innate Immune Mechanisms of IPF

Molecular Pathogenesis of Pulmonary Fibrosis, with Focus on Pathways Related to TGF-β and the Ubiquitin-Proteasome Pathway

The Sphingosine Kinase 1 Inhibitor, PF543, Mitigates Pulmonary Fibrosis by Reducing Lung Epithelial Cell mtDNA Damage and Recruitment of Fibrogenic Monocytes

Cleavage factor 25 deregulation contributes to pulmonary fibrosis through alternative polyadenylation

Immune cells crosstalk Pathways, and metabolic alterations in Idiopathic pulmonary fibrosis

Targeting the PI3K/mTOR pathway in idiopathic pulmonary fibrosis: Advances and therapeutic potential

Molecular Biomarkers in Idiopathic Pulmonary Fibrosis: State of the Art and Future Directions